

		<b>EMLc</b>	ATC codes: <b>L01CA02</b>
<b>Indication</b>	Malignant neoplasms of kidney, except renal pelvis	ICD11 code: <b>2D40.Z</b>	
<b>INN</b>	Vincristine		
<b>Medicine type</b>	Chemical agent		
<b>List type</b>	Complementary (EML) (EMLc)		
<b>Formulations</b>	Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate) ; 5 mg in vial (vincristine sulfate) ; 1 mg per mL in vial (vincristine sulfate) ; 2 mg per 2 mL in vial (vincristine sulfate)		
<b>EML status history</b>	First added in 2011 ( <a href="#">TRS 965</a> ) Changed in 2015 ( <a href="#">TRS 994</a> ) Changed in 2021 ( <a href="#">TRS 1035</a> )		
<b>Sex</b>	All		
<b>Age</b>	Also recommended for children		
<b>Therapeutic alternatives</b>	The recommendation is for this specific medicine		
<b>Patent information</b>	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> . 		
<b>Tags</b>	<span>Cancer</span>		
<b>Wikipedia</b>	<a href="#">Vincristine</a> 		
<b>DrugBank</b>	<a href="#">Vincristine</a> 		

## Summary of evidence and Expert Committee recommendations

The Expert Committee recommended the addition of new strength formulations of vincristine IV injection (1mg/mL and 2 mg/2mL) to the EML and EMLc.

[Expert Committee report](#) 

